Good question, but I would guess it doesn’t have anything to do with Follica’s wounding protocol (which they licensed from Dr. Cotsarelis). I think these are 2 separate ventures, both business wise and conceptually. If Cots wanted to augment the PGD2 blocker with wounding, and he had an exclusive agreement with Follica for the wounding part, he would have to abrogate or rescind that agreement with Follica and that would be very hard to do.
If Follica has been relatively silent since this hit, I think it’s more because PGD2 is where Cots’ attention has been going these past 2 years and Follica may be resigned to the fact that they’ve stalled and others are moving well beyond them.
I think the PGD2 blocker thing is meant to be a separate protocol from the wounding idea, and they’re not related other than the fact that they were both based on Dr. Cotsarelis’ research. The PGD2 blocker thing is meant to work on its own.
Another thing about Follica and wounding is that I think that any procedures involving wounding are now obsolete. The existing science has moved well beyond that. Wounding was only ever relevant because it unleashed growth factors in the skin that would have been provided by activated stem cells. Wounding became relevant because nobody really knew how to use pluripotent stem cells. They were hard to culture, it was very hard to get permission to use them, and they couldn’t be manipulated, at least not with the technology that was around a few years ago. But now researchers are actually using stem cells themselves. So wounding procedures have been rendered obsolete. Wounding is “yesterday’s news”.
Thanks for posting that and finding all this interesting stuff for us…